ArticleThe American journal of gastroenterology2015
Fecal Microbiota in Pediatric Inflammatory Bowel Disease and Its Relation to Inflammation.
Article in The American journal of gastroenterology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 135 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
135 citing papers in PubMed, 5 syntheses or guidelines pooled it, 244 citations in OpenAlex.
- Infliximab-linked gut microbiome signatures as candidate treatment response biomarkers in pediatric inflammatory bowel disease: a systematic review.Frontiers in pharmacology · 2026Pooled it
- Is the microbiome the answer to inflammatory bowel disease: systematic review.Langenbeck's archives of surgery · 2025Pooled it
- Gut microbiome-associated predictors as biomarkers of response to advanced therapies in inflammatory bowel disease: a systematic review.Gut microbes · 2023Pooled it
- A Systematic Overview of Type II and III Toxin-Antitoxin Systems with a Focus on Druggability.Toxins · 2018Pooled it
- Lower Level ofBioMed research international · 2016Pooled it
- Infant gut microbiota characteristics generally do not modify effects of lipid-based nutrient supplementation on growth or inflammation: secondary analysis of a randomized controlled trial in Malawi.Scientific reports · 2020Trial
- The combination of wheat peptides and fucoidan protects against chronic superficial gastritis and alters gut microbiota: a double-blinded, placebo-controlled study.European journal of nutrition · 2020Trial
- Timing for the second fecal microbiota transplantation to maintain the long-term benefit from the first treatment for Crohn's disease.Applied microbiology and biotechnology · 2019Trial
- C4B gene influences intestinal microbiota through complement activation in patients with paediatric-onset inflammatory bowel disease.Clinical and experimental immunology · 2017Trial
- Functional Gut Microbiota Alterations in Patients with Inflammatory Bowel Disease Receiving Long-Term Biologic Therapy: A Pilot Comparative Study.Journal of clinical medicine · 2026Article
- Review
- Decoding the power of the microbiome in human health.Frontiers in cellular and infection microbiology · 2026Review
- Integrating multi-omics data to reveal the host-microbiota interactome in inflammatory bowel disease.Gut microbes · 2025Review
- Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities.Nature reviews. Microbiology · 2025Review
- Molecular Insight into the Role of HLA Genotypes in Immunogenicity and Secondary Refractoriness to Anti-TNF Therapy in IBD Patients.International journal of molecular sciences · 2025Review
- Intestinal Microbiota and Fecal Transplantation in Patients with Inflammatory Bowel Disease andJournal of clinical medicine · 2025Review
- Unveiling the diagnostic and pro-inflammatory role of crohn's disease: insights from 16 S-guided discovery and species-specific validation.BMC gastroenterology · 2025Article
- Irritable Bowel Syndrome with Diarrhea (IBS-D): Effects ofMicroorganisms · 2025Article
- Gut Microbiota in Different Treatment Response Types of Crohn's Disease Patients Treated with Biologics over a Long Disease Course.Biomedicines · 2025Article
- Fecal microbiota and genetics in pediatric-onset orofacial granulomatosis and Crohn´s disease.Scientific reports · 2025Article
75 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesInflammatory bowel disease (IBD) is considered to result from interplay between host and intestinal microbiota. While IBD in adults has shown to be associated with marked changes in the intestinal microbiota, there are only a few studies in children, and particularly studies focusing on therapeutic responses are lacking. Hence, this prospective study addressed the intestinal microbiota in pediatric IBD especially related to the level of inflammation.
methodsIn total, 68 pediatric patients with IBD and 26 controls provided stool and blood samples in a tertiary care hospital and 32 received anti-tumor necrosis factor-α (anti-TNF-α). Blood inflammatory markers and fecal calprotectin levels were determined. The intestinal microbiota was characterized by phylogenetic microarray and qPCR analysis.
resultsThe microbiota varied along a gradient of increasing intestinal inflammation (indicated by calprotectin levels), which was associated with reduced microbial richness, abundance of butyrate producers, and relative abundance of Gram-positive bacteria (especially Clostridium clusters IV and XIVa). A significant association between microbiota composition and inflammation was indicated by a set of bacterial groups predicting the calprotectin levels (area under curve (AUC) of 0.85). During the induction of anti-TNF-α, the microbial diversity and similarity to the microbiota of controls increased in the responder group by week 6, but not in the non-responders (P<0.01; response related to calprotectin levels). The abundance of six groups of bacteria including those related to Eubacterium rectale and Bifidobacterium spp. predicted the response to anti-TNF-α medication.
conclusionsIntestinal microbiota represents a potential biomarker for correlating the level of inflammation and therapeutic responses to be further validated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.